Safety
toxicities, leukopenia
ADVERSE EVENTS, TOXIC EPIDERMAL NECROLYSIS (TEN), LEUKOPENIA
A summary of toxicities possibly related to camrelizumab and/or apatinib that occurred in ≥ 10% of patients is presented in Treatment related adverse events occurred in ≥ 10% of patients.Two patients discontinued treatment due to AEs. One patient experienced grade 3 leukopenia and discontinued oral apatinib. Considering that PD-1 inhibitor monotherapy was not defined as a standard treatment, the patient withdrew from the study. Another patient discontinued the treatment due to grade 4 toxic epidermal necrolysis (TEN), which was relieved after steroid treatment.